Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a regenerative medicine company focused on stem cell-based therapies and products, and its news flow reflects activity across clinical development, intellectual property, commercialization, and capital markets. The company develops therapeutic products using adult stem cell protocols, with core programs in disc and spine disease, metabolic disorders, and a commercial BioCosmeceutical platform.
News about BRTX often centers on its disc/spine program (brtxDISC™) and lead cell therapy candidate BRTX-100. Recent announcements include Fast Track designation from the U.S. Food and Drug Administration (FDA) for the BRTX-100 Phase 2 trial in chronic lumbar disc disease and the granting of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application approval pathway. Updates also cover blinded Phase 2 clinical data presented at scientific meetings and the status of enrollment and trial progress.
Another key news theme is the ThermoStem® metabolic program, where BioRestorative has reported milestones such as a Notice of Allowance from the Japanese Patent Office for its allogeneic, off-the-shelf brown adipose-derived stem cell technology designed to treat obesity and metabolic disorders. Press releases describe how this intellectual property strengthens protection for cell-based approaches that aim to generate brown adipose tissue and utilize exosomes secreted by brown adipose-derived stem cells.
Investors following BRTX news will also see coverage of the company’s BioCosmeceutical platform, including commercial developments for its cell-based secretome serum, as well as corporate events such as equity financings, stock repurchase authorizations, conference presentations, and quarterly financial results. This page aggregates these updates so readers can track BioRestorative’s clinical, commercial, and financial disclosures in one place.
BioRestorative Therapies (NASDAQ:BRTX) will attend the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026, to pursue commercialization of its BioCosmeceutical platform.
Commercial leadership, led by Crystal Romano, will meet potential partners, distributors, and practitioners to expand awareness, distribution, and adoption of regenerative skincare products using biologically active secretome components.
BioRestorative Therapies (NASDAQ:BRTX) reported several near‑term and strategic advances: completed enrollment of 99 patients in its randomized, sham‑controlled Phase 2 BRTX‑100 trial, received a positive FDA Type B meeting aligning on Phase 3 and CMC, initiated Phase 3 enabling activities, and raised $5.0 million in a public offering to strengthen its balance sheet.
The company is also expanding a BioCosmeceutical commercial platform and advancing ThermoStem® IP while targeting a Phase 3 IND amendment in H2 2026 and Phase 2 topline results in early 2027.
BioRestorative (NASDAQ:BRTX) announced that IP Australia allowed Patent Application No. 2020265664 on Feb. 24, 2026, covering non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates and methods of making them.
The allowance extends ThermoStem®'s Australian IP protection, focuses on an allogeneic, off-the-shelf BADSC platform for obesity and metabolic disorders, and signals continued global patent portfolio building for next-generation, cell-based alternatives to GLP-1 drugs.
BioRestorative Therapies (NASDAQ:BRTX) closed a public offering on Feb 13, 2026, raising approximately $5.0 million gross through sale of 14,285,715 common shares (or pre-funded warrants) and warrants to purchase 14,285,715 shares at $0.35 per share.
The warrants are immediately exercisable, expire in five years, and net proceeds will fund BRTX-100 clinical trials, ThermoStem preclinical R&D, biocosmeceuticals development, and general corporate purposes.
BioRestorative Therapies (NASDAQ:BRTX) priced a public offering of 14,285,715 common shares (or pre-funded warrants) plus warrants to purchase 14,285,715 shares at a combined public offering price of $0.35 per share and accompanying warrant.
The warrants carry a $0.35 exercise price, are exercisable immediately, expire five years after issuance, and the offering is expected to close on or about February 13, 2026, raising gross proceeds of approximately $5.0 million before fees. Rodman & Renshaw is the placement agent. Proceeds are intended for BRTX-100 clinical trials, ThermoStem preclinical R&D, biocosmeceuticals development, and general corporate purposes.
BioRestorative (NASDAQ:BRTX) reported a positive Type B meeting with the U.S. FDA on Feb 11, 2026, regarding a potential expedited BLA pathway for its Fast-Track-designated BRTX-100 program for chronic lumbar disc disease (cLDD).
The FDA raised no clinical safety concerns from the ongoing 99-patient Phase 2 trial, endorsed the proposed Phase 3 design (outcomes, dosing, eligibility), sample size, and powering assumptions pending final IND review, and confirmed alignment on ongoing CMC activities. The company has begun Phase 3 enabling work and aims to submit the Phase 3 IND in second half of 2026.
BioRestorative (NASDAQ:BRTX) announced on Feb 10, 2026 that it completed enrollment of 99 patients in its Phase 2 trial of BRTX-100 for chronic lumbar disc disease (cLDD). The randomized 2:1, double-blind, sham-controlled single-disc study has primary endpoints at week 52 for ODI and VAS improvements.
The company says this is the largest FDA-authorized Phase 2 cell-therapy trial in cLDD and that ~40% of enrollment occurred in the past six months, strengthening the pathway toward Phase 3 and a potential BLA discussion.
BioRestorative (NASDAQ:BRTX) has been granted a Type B meeting with the U.S. FDA to discuss a potential accelerated BLA approval pathway for the Fast-Track-designated investigational therapy BRTX-100 in chronic lumbar disc disease (cLDD).
The meeting is scheduled for mid-December 2025. Management said Phase 2 analyses have shown consistently positive safety and efficacy signals to date and that the company will request an accelerated timeline to enter a Phase 3 trial to support a BLA. BioRestorative will provide investor updates only after it has received and reviewed the FDA's written meeting minutes.
BioRestorative Therapies (NASDAQ:BRTX) reported Q3 2025 results on Nov 12, 2025, and provided a business update.
Key figures: Q3 revenue $11,800 (royalty only) versus $233,600 in Q3-2024; loss from operations $3.7M; net loss $3.0M, $0.33 per share; cash and marketable securities $4.5M at quarter end plus ~$1.085M gross raised subsequent to quarter end via a registered direct offering.
Corporate and development updates include a registered direct financing (678,125 shares at $1.60) with 508,592 warrants, Fast Track designation and anticipated FDA Type B meeting for BRTX-100, a Japanese Notice of Allowance for the ThermoStem platform, and a new Head of Global Commercial Operations.
BioRestorative Therapies (NASDAQ:BRTX) will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025.
Management will host a conference call at 4:30 p.m. ET the same day to review results and provide a business update. Dial-in numbers are Domestic: 1-888-506-0062, International: 1-973-528-0011 with Access Code: 464585. The call will be broadcast live and archived in the Investors section under News & Events/IR Calendar on the company website.